Multi-arm Optimization of Stroke Thrombolysis (MOST)

  • End date
    Apr 19, 2025
  • participants needed
  • sponsor
    Washington University School of Medicine
Updated on 19 June 2022


The primary efficacy objective of the MOST trial is to determine if argatroban (100µg/kg bolus followed by 3µg/kg per minute for 12 hours) or eptifibatide (135µg/kg bolus followed by 0.75µg/kg/min infusion for two hours) results in improved 90-day modified Rankin scores (mRS) as compared with placebo in acute ischemic stroke (AIS) patients treated with standard of care thrombolysis (0.9mg/kg IV rt-PA or 0.25mg/kg IV tenecteplase or TNK) within three hours of symptom onset. Patients may also receive endovascular thrombectomy (ET) per usual care. Time of onset is defined as the last time the patient was last known to be well.

Condition Acute Ischemic Stroke
Treatment Placebo, Eptifibatide, Argatroban
Clinical Study IdentifierNCT03735979
SponsorWashington University School of Medicine
Last Modified on19 June 2022


Yes No Not Sure

Inclusion Criteria

Acute ischemic stroke patients
Treated with 0.9mg/kg IV rt-PA or 0.25mg/kg IV TNK within 3 hours of stroke onset or time last known well
Age ≥ 18
NIHSS score ≥ 6 prior to IV thrombolysis
Able to receive assigned study drug within 60 minutes but no later than 75 minutes of initiation of IV thrombolysis

Exclusion Criteria

Known allergy or hypersensitivity to argatroban or eptifibatide
Previous stroke in the past 90 days
Previous intracranial hemorrhage, neoplasm, subarachnoid hemorrhage, or arterial venous malformation
Clinical presentation suggested a subarachnoid hemorrhage, even if initial CT scan was normal
Any surgery, or biopsy of parenchymal organ in the past 30 days
Trauma with internal injuries or ulcerative wounds in the past 30 days
Severe head trauma in the past 90 days
Systolic blood pressure persistently >180mmHg post-IV thrombolysis despite antihypertensive intervention
Diastolic blood pressure persistently >105mmHg post-IV thrombolysis despite antihypertensive intervention
Serious systemic hemorrhage in the past 30 days
Known hereditary or acquired hemorrhagic diathesis, coagulation factor deficiency, or oral anticoagulant therapy with INR >1.5
Positive urine or serum pregnancy test for women of child bearing potential
Glucose <50 or >400 mg/dl
Platelets <100,000/mm3
Hematocrit <25 %
Elevated pre-thrombolysis PTT above laboratory upper limit of normal
Creatinine > 4 mg/dl
Ongoing renal dialysis, regardless of creatinine
Received Low Molecular Weight heparins (such as Dalteparin, Enoxaparin, Tinzaparin) in full dose within the previous 24 hours
Abnormal PTT within 48 hours prior to randomization after receiving heparin or a direct thrombin inhibitor (such as bivalirudin, argatroban, dabigatran or lepirudin)
Received Factor Xa inhibitors (such as Fondaparinaux, apixaban or rivaroxaban) within the past 48 hours
Received glycoprotein IIb/IIIa inhibitors within the past 14 days
Pre-existing neurological or psychiatric disease which confounded the neurological or functional evaluations e.g., baseline modified Rankin score >3
Other serious, advanced, or terminal illness or any other condition that the investigator felt would pose a significant hazard to the patient if rt-PA, TNK, eptifibatide or argatroban therapy was initiated
Example: known cirrhosis or clinically significant hepatic disease
Current participation in another research drug treatment or interventional device
Informed consent from the patient or the legally authorized representative was not or could not be obtained
trial - Subjects could not start another experimental agent until after 90
High density lesion consistent with hemorrhage of any degree
Large (more than 1/3 of the middle cerebral artery) regions of clear hypodensity on the baseline CT Scan. Sulcal effacement and/or loss of grey-white differentiation alone are not contraindications for treatment
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note